← Leaderboards
Cynthia E Dunbar
Heart, Lung, And Blood Institute
$0
Attributed
$0
Total exposure
0
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding mix
By agency
—
By mechanism
—
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Macaca Mulatta”
- Barton F Haynes · Duke University$291,595,855
- Peter Gordon Gillespie · Oregon Health And Science University$83,402,374
- Richard A Gibbs · Baylor College Of Medicine$82,928,769
- Dan H. Barouch · Fred Hutchinson Cancer Center$67,567,747
- David I Watkins · George Washington University$57,087,952
- Rama Rao Amara · Emory University$54,145,017
Research focus
Macaca MulattaIn VivoGene TherapyHematopoiesisCellsGenesHematopoietic Stem CellsStem CellsHematopoieticTransplantationCd34 GeneGeneticIn VitroMarrowSafetyVectorAnimalsNonhuman PrimateEngraftmentBaseMacacaCollaborationsLentivirus VectorPrimates
Grant awards (74)
Clonal and imaging analyses of in vivo hematopoiesis, immune cell ontogeny and adoptive cell therapies$1,745,118
ZIA · FY2025 · HL · contact PI
Investigation of underlying mechanisms and novel therapies for human acquired and congenital disorders of hematopoiesis$1,308,839
ZIA · FY2025 · HL · contact PI
Optimization of genetic modification of HSCs in the NHP model and creation of relevant preclinical models of human disease and therapies$1,308,839
ZIA · FY2025 · HL · contact PI
Optimization of genetic modification of HSCs in the NHP model and creation of relevant preclinical models of human disease and therapies$2,130,169
ZIA · FY2024 · HL · contact PI
Clonal and imaging analyses of in vivo hematopoiesis, immune cell ontogeny and adoptive cell therapies$1,981,553
ZIA · FY2024 · HL · contact PI
Investigation of underlying mechanisms and novel therapies for human acquired and congenital disorders of hematopoiesis$743,082
ZIA · FY2024 · HL · contact PI
Macaque models for preclinical development of iPSCs$99,078
ZIA · FY2024 · HL · contact PI
Clonal and imaging analyses of in vivo hematopoiesis, immune cell ontogeny and adoptive cell therapies$1,829,402
ZIA · FY2023 · HL · contact PI
Optimization of genetic modification of HSCs in the NHP model and creation of relevant preclinical models of human disease and therapies$1,829,402
ZIA · FY2023 · HL · contact PI
Novel therapies for bone marrow failure and Diamond-Blackfan Anemia$686,026
ZIA · FY2023 · HL · contact PI
Macaque models for preclinical development of iPSCs$228,675
ZIA · FY2023 · HL · contact PI
Optimization of genetic modification of HSCs in the NHP model and creation of relevant preclinical models of human disease and therapies$1,318,233
ZIA · FY2022 · HL · contact PI
Clonal and imaging analyses of in vivo hematopoiesis, immune cell ontogeny and adoptive cell therapies$1,318,233
ZIA · FY2022 · HL · contact PI
Eltrombopag for bone marrow failure and Diamond-Blackfan Anemia$514,058
ZIA · FY2022 · HL · contact PI
Macaque models for preclinical development of iPSCs$171,353
ZIA · FY2022 · HL · contact PI
Clonal and imaging analyses of in vivo hematopoiesis, immune cell ontogeny and adoptive cell therapies$1,481,031
ZIA · FY2021 · HL · contact PI
Optimization of genetic modification of HSCs in the NHP model and creation of relevant preclinical models of human disease and therapies$1,481,031
ZIA · FY2021 · HL · contact PI
Eltrombopag for bone marrow failure and Diamond-Blackfan Anemia$555,386
ZIA · FY2021 · HL · contact PI
Macaque models for preclinical development of iPSCs$185,129
ZIA · FY2021 · HL · contact PI
Optimization of gene transfer and gene editing safety and efficacy focusing on the NHP model$1,731,502
ZIA · FY2020 · HL · contact PI
Clonal analysis of in vivo hematopoiesis$1,539,113
ZIA · FY2020 · HL · contact PI
Eltrombopag for bone marrow failure$384,778
ZIA · FY2020 · HL · contact PI
Macaque and human models for preclinical development of iPSCs$192,389
ZIA · FY2020 · HL · contact PI
Optimization of gene transfer and gene editing safety and efficacy focusing on the NHP model$1,543,957
ZIA · FY2019 · HL · contact PI
Clonal analysis of in vivo hematopoiesis$1,543,957
ZIA · FY2019 · HL · contact PI
Macaque and human models for preclinical development of iPSCs$410,089
ZIA · FY2019 · HL · contact PI
Eltrombopag for bone marrow failure$410,089
ZIA · FY2019 · HL · contact PI
Clonal analysis of in vivo hematopoiesis$1,661,256
ZIA · FY2018 · HL · contact PI
Optimization of gene transfer and gene editing safety and efficacy focusing on the NHP model$1,661,256
ZIA · FY2018 · HL · contact PI
Eltrombopag for bone marrow failure$396,316
ZIA · FY2018 · HL · contact PI
Macaque and human models for preclinical development of iPSCs$396,316
ZIA · FY2018 · HL · contact PI
Clonal analysis of in vivo hematopoiesis$1,590,278
ZIA · FY2017 · HL · contact PI
Optimization of gene transfer and gene editing safety and efficacy focusing on the NHP model$1,063,173
ZIA · FY2017 · HL · contact PI
Macaque and human models for preclinical development of iPSCs$518,303
ZIA · FY2017 · HL · contact PI
Eltrombopag for bone marrow failure$341,641
ZIA · FY2017 · HL · contact PI
Clonal analysis of in vivo hematopoiesis$1,653,638
ZIA · FY2016 · HL · contact PI
Macaque and human models for preclinical development of iPSCs$1,157,547
ZIA · FY2016 · HL · contact PI
Optimization of gene transfer and gene editing safety and efficacy focusing on the NHP model$330,728
ZIA · FY2016 · HL · contact PI
Eltrombopag for bone marrow failure$165,364
ZIA · FY2016 · HL · contact PI
Clonal analysis of in vivo hematopoiesis$1,303,534
ZIA · FY2015 · HL · contact PI
Macaque and human models for preclinical development of iPSCs$1,013,860
ZIA · FY2015 · HL · contact PI
Optimization of gene transfer safety and efficacy focusing on the NHP model$434,511
ZIA · FY2015 · HL · contact PI
Eltrombopag for bone marrow failure$144,837
ZIA · FY2015 · HL · contact PI
Retroviral Mediated Gene Transfer Into Primate Hematopoietic Cells$3,125,121
ZIC · FY2014 · HL · contact PI
Clonal analysis of in vivo hematopoiesis$1,205,414
ZIA · FY2014 · HL · contact PI
Macaque and human models for preclinical development of iPSCs$1,205,414
ZIA · FY2014 · HL · contact PI
Optimization of gene transfer safety and efficacy focusing on the NHP model$614,238
ZIA · FY2014 · HL · contact PI
Eltrombopag for bone marrow failure$46,125
ZIA · FY2014 · HL · contact PI
Retroviral Mediated Gene Transfer Into Primate Hematopoietic Cells$4,078,100
ZIC · FY2013 · HL · contact PI
Macaque and human models for preclinical development of iPSCs$1,009,452
ZIA · FY2013 · HL · contact PI
In vivo hematopoiesis$1,009,452
ZIA · FY2013 · HL · contact PI
Optimization of gene transfer safety and efficacy focusing on the NHP model$507,672
ZIA · FY2013 · HL · contact PI
Retroviral Mediated Gene Transfer Into Primate Hematopoietic Cells$2,624,810
ZIC · FY2012 · HL · contact PI
Developing Efficient and Safe Gene Transfer to Primate Hematopoietic Stem Cells$1,934,337
ZIA · FY2012 · HL · contact PI
Understanding hematopoietic stem cell mobilization and engraftment$1,547,470
ZIA · FY2012 · HL · contact PI
The rhesus macaque as a preclinical model for induced pluripotent stem cells$386,867
ZIA · FY2012 · HL · contact PI
Retroviral Mediated Gene Transfer Into Primate Hematopoietic Cells$2,523,821
ZIC · FY2011 · HL · contact PI
Developing Efficient and Safe Gene Transfer to Primate Hematopoietic Stem Cells$1,752,245
ZIA · FY2011 · HL · contact PI
Enhancement of hematopoietic stem cell mobilization and engraftment$1,401,796
ZIA · FY2011 · HL · contact PI
The rhesus macaque as a preclinical model for induced pluripotent stem cells$350,449
ZIA · FY2011 · HL · contact PI
Retroviral Mediated Gene Transfer Into Primate Hematopoietic Cells$3,797,770
ZIC · FY2010 · HL · contact PI
Developing Efficient and Safe Gene Transfer to Primate Hematopoietic Stem Cells$1,056,912
ZIA · FY2010 · HL · contact PI
The rhesus macaque as a preclinical model for induced pluripotent stem cells$924,798
ZIA · FY2010 · HL · contact PI
Enhancement of hematopoietic stem cell mobilization and engraftment$660,570
ZIA · FY2010 · HL · contact PI
Gene Transfer And Ex Vivo Manipulation Of Stem Cells$6,125,712
ZIA · FY2009 · HL · contact PI
Gene Transfer And Ex Vivo Manipulation Of Hematopoietic Cells$2,566,909
Z01 · FY2008 · HL · contact PI
Gene Transfer And Ex Vivo Manipulation Of Hematopoietic Cells$3,605,498
Z01 · FY2007 · HL · contact PI
Gene Transfer And Ex Vivo Manipulation Of Hematopoietic$0
Z01 · FY2006 · HL · contact PI
Gene Transfer And Ex Vivo Manipulation Of Hematopoietic$0
Z01 · FY2005 · HL
Gene Transfer And Ex Vivo Manipulation Of Hematopoietic$0
Z01 · FY2004 · HL
Gene Transfer And Ex Vivo Manipulation Of Hematopoietic$0
Z01 · FY2003 · HL
Gene Transfer And Ex Vivo Manipulation Of Hematopoietic$0
Z01 · FY2002 · HL
Gene Transfer And Ex Vivo Manipulation Of Hematopoietic$0
Z01 · FY2001 · HL
GENE TRANSFER AND EX VIVO MANIPULATION OF HEMATOPOIETIC CELLS$0
Z01 · FY2000 · HL